1 From The Division of Pediatric Cardiology, The New York Hospital-Cornell Medical Center, New York
Since January 1980, 110 children having 113 attacks of Kawasaki syndrome were studied. Age at onset was 7 weeks to 12 years (mean 36/12 years, median 29/12 years); 77% were younger than 5 years of age; the male to female ratio was 1.8; racial distribution was 52% white, 19% black, 14% Hispanic, and 16% Asian. Protocol of management consisted of high-dose aspirin (100 mg/kg/d) until afebrile, and then 81 mg every day until free of coronary aneurysm. Two-dimensional echocardiograms were done weekly during the acute stage, at 2 and 6 months after onset, and yearly if a coronary abnormality was detected. At 1 month, 51 coronary arterial abnormalities were present in 25 patients. Risk factors for a coronary abnormality were duration of fever greater than or equal to 2 weeks, level of platelet count, marked elevation of ESR, and age younger than 5 years. No statistically significant difference in incidence of aneurysms was detected between patients on high-dose aspirin and those on medium- or low-dose aspirin.
Key Words: aspirin Kawasaki syndrome coronary artery
Submitted on October 13, 1986
Accepted on February 10, 1987
This article has been cited by other articles:
![]() |
J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association Pediatrics, December 1, 2004; 114(6): 1708 - 1733. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association Circulation, October 26, 2004; 110(17): 2747 - 2771. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. T. Saulsbury Comparison of High-Dose and Low-Dose Aspirin Plus Intravenous Immunoglobulin in the Treatment of Kawasaki Syndrome Clinical Pediatrics, October 1, 2002; 41(8): 597 - 601. [Abstract] [PDF] |
||||
![]() |
J. W Newburger and J. C Burns Kawasaki disease Vascular Medicine, August 1, 1999; 4(3): 187 - 202. [Abstract] [PDF] |
||||
![]() |
W. P. Wright, M. A. Alpert, V. Mukerji, and C. J. Santolin Coronary Artery Aneurysms A Case Study and Literature Review Angiology, August 1, 1991; 42(8): 672 - 679. [Abstract] [PDF] |
||||
![]() |
CARDIAC INVOLVEMENT IN KAWASAKI SYNDROME IS UNRELATED TO ASPIRIN DOSAGE Journal Watch (General), January 1, 1988; 1988(101): 3 - 3. [Full Text] |
||||